Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Karyopharm Therapeutics (KPTI) Gains from Investment Securities (2016 - 2023)

Historic Gains from Investment Securities for Karyopharm Therapeutics (KPTI) over the last 12 years, with Q4 2023 value amounting to $3000.0.

  • Karyopharm Therapeutics' Gains from Investment Securities rose 20000.0% to $3000.0 in Q4 2023 from the same period last year, while for Mar 2024 it was $4000.0, marking a year-over-year increase of 16666.67%. This contributed to the annual value of $3.6 million for FY2024, which is N/A changed from last year.
  • As of Q4 2023, Karyopharm Therapeutics' Gains from Investment Securities stood at $3000.0, which was up 20000.0% from $1000.0 recorded in Q2 2023.
  • Karyopharm Therapeutics' Gains from Investment Securities' 5-year high stood at $11.7 million during Q1 2019, with a 5-year trough of -$231000.0 in Q2 2021.
  • Over the past 5 years, Karyopharm Therapeutics' median Gains from Investment Securities value was $2000.0 (recorded in 2022), while the average stood at $1.9 million.
  • Within the past 5 years, the most significant YoY rise in Karyopharm Therapeutics' Gains from Investment Securities was 20000.0% (2023), while the steepest drop was 30000.0% (2023).
  • Karyopharm Therapeutics' Gains from Investment Securities (Quarter) stood at $11.7 million in 2019, then decreased by 3.71% to $11.3 million in 2020, then tumbled by 98.43% to $177000.0 in 2021, then crashed by 101.69% to -$3000.0 in 2022, then surged by 200.0% to $3000.0 in 2023.
  • Its Gains from Investment Securities was $3000.0 in Q4 2023, compared to $1000.0 in Q2 2023 and -$4000.0 in Q1 2023.